StockData
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. (VVOS) stock

VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.08−0.00 (-4.64%)

Close on Nov 18, 2026Market cap $1.53MP/E –Yield –

Vivos Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Vivos Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $20.90M, up 45.2% year over year. For fiscal 2025 it was $17.44M, up 16.0% from the year before. The highest annual figure on record is $17.44M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.44M+16.0%
FY2024Dec 31, 2024$15.03M+8.9%
FY2023Dec 31, 2023$13.80M-13.9%
FY2022Dec 31, 2022$16.02M-5.1%
FY2021Dec 31, 2021$16.89M+29.2%
FY2020Dec 31, 2020$13.07M+14.7%
FY2019Dec 31, 2019$11.39M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.15M+34.9%
Q1 FY2026Mar 31, 2026$5.14M+70.5%
Q4 FY2025Dec 31, 2025$3.82M+3.4%
Q3 FY2025Sep 30, 2025$6.78M+75.7%
Q2 FY2025Jun 30, 2025$3.82M-5.8%
Q1 FY2025Mar 31, 2025$3.02M-11.8%
Q4 FY2024Dec 31, 2024$3.70M+13.9%
Q3 FY2024Sep 30, 2024$3.86M+16.9%
Q2 FY2024Jun 30, 2024$4.05M+19.4%
Q1 FY2024Mar 31, 2024$3.42M-11.4%
Q4 FY2023Dec 31, 2023$3.25M-17.8%
Q3 FY2023Sep 30, 2023$3.30M-22.3%
Q2 FY2023Jun 30, 2023$3.40M-18.9%
Q1 FY2023Mar 31, 2023$3.86M+5.8%
Q4 FY2022Dec 31, 2022$3.95M-10.1%
Q3 FY2022Sep 30, 2022$4.25M-6.6%
Q2 FY2022Jun 30, 2022$4.18M-7.0%
Q1 FY2022Mar 31, 2022$3.64M+5.7%
Q4 FY2021Dec 31, 2021$4.39M+32.9%
Q3 FY2021Sep 30, 2021$4.55M+38.1%
Q2 FY2021Jun 30, 2021$4.50M+37.5%
Q1 FY2021Mar 31, 2021$3.45M+7.9%
Q4 FY2020Dec 31, 2020$3.31M–
Q3 FY2020Sep 30, 2020$3.29M–
Q2 FY2020Jun 30, 2020$3.27M–
Q1 FY2020Mar 31, 2020$3.20M–

More Vivos Therapeutics figures

See a number that looks wrong?